Kent Imaging Welcomes Clinical Leader, Dr. Adam Landsman, DPM, PhD as Chief Medical Officer

Dr. Landsman’s exceptional background as the Assistant Professor of Surgery at Harvard Medical School will further Kent’s medical device applications.

CALGARY, Nov. 14, 2017 /CNW/ – Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, today announced that Dr. Adam Landsman, DPM, PhD has joined the company as Chief Medical Officer. Dr. Landsman will serve the team with his clinical background and guide the medical uses of Kent’s technology.

“Kent’s leading edge technology provides physicians and surgeons value based tissue oxygen saturation levels which are key to improved decision making while reducing costs in wound care and surgical healing,” said Dr. Adam Landsman, DPM, PhD, Chief of Division of Podiatric Surgery at the Cambridge Health Alliance (Harvard Medical School). “I have had the opportunity to clinically study and research the benefits of Kent’s device. Seeing the value and understanding the practical need for Kent’s technology in the clinic, I was eager to join the team behind it.”

“I am pleased to have Dr. Landsman, a proven leader with extensive research and clinical expertise, join our team at Kent,” said Pierre Lemire, CEO of Kent Imaging. “This is an exciting time for Kent Imaging as we welcome Dr. Landsman and launch our FDA cleared SnapshotNIR device.”

Dr. Landsman is the Assistant Professor of Surgery at Harvard Medical School. Dr. Landsman holds a PhD and MS in Bioengineering from the University of Pennsylvania, DPM in Podiatric Medicine and Surgery from the Temple University, Pennsylvania College of Podiatric Medicine in which he was the first simultaneous dual degree (DPM/PhD) student in the history of podiatric medical education. Dr. Landsman also holds a BS in Chemical Engineering and English Literature from the University of Virginia.

About Kent Imaging Inc.
Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns and cardiac specialties.  The team at Kent Imaging is committed to improving patient outcomes by delivering innovative and practical solutions for the healthcare industry. Kent Imaging holds multiple patents in medical technology and is currently commercializing the breakthrough multispectral imaging solutions that assesses tissue oxygen saturation. The company is headquartered in Calgary, Alberta, Canada, and has locations in Chicago, Los Angeles, Salt Lake City and Seattle.

Kent’s SnapshotNIR is U.S. Food and Drug Administration 510(k) cleared, and Health Canada licensed. The device is available for sale in the United States and Canada. Improving on Kent’s previous KC103, the handheld Kent SnapshotNIR is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. Tissue oxygen saturation measurements provide critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes.

Kent Imaging Inc., Vonda-Lee Sharun – Marketing Manager, press@kentimaging.com

Kent Imaging Hires Chief Scientist to Lead Product Research

Kent Imaging announced today the hiring of Dr. Michael Sowa for the role of Chief Scientist. Dr. Sowa brings over 24 years of structured research from his role as Group Leader and Principal Research Officer at the National Research Council of Canada (NRC). During his time at the NRC his was instrumental in their development of ICG angiography which technology lead to the creation of Novadaq and then went on to lead the team that developed the next generation of imaging technology – NIR spectroscopy which formed the basis of Kent’s products. Dr. Sowa will continue to lead the development of medical imaging being developed by Kent Imaging while also be responsible for Kent’s IP strategy.

Kent Imaging Appoints Healthcare Veteran as CEO

Kent Imaging announced today the appointment of seasoned medical imaging executive Pierre Lemire to the role of Chief Executive Officer. Mr. Lemire brings more than 30 years of experience in successfully launching new products to market. Prior to joining Kent Imaging, he co-founded Calgary Scientific and as President, led the company in becoming a global leader in medical imaging. He was also previously Chief Technology Officer for Autodesk, a Silicon Valley company. Kent founder Don Chapman will continue in his role as Executive Chairman assisting Mr. Lemire in launching the company’s new handheld imaging device.

Co-Developed OCT Spectroscopy Device Moving to Clinical Testing

Kent Imaging announced today that an OCT spectroscopy device, co-developed with the National Research Council of Canada (NRC), is moving to clinical testing. The completed new technology is being transported to a Toronto hospital to begin the first stage of clinical testing.

Italian Research Group Initiate Study

An Italian research group has submitted a protocol which will use the Kent Camera in an upcoming study to examining the benefits of hyperbaric oxygen therapy in venous ulcers. The study will recruit approximately 80 patients with venous ulcers. The Kent Camera will be used to non-invasively detect levels of oxy-hemoglobin and deoxy-hemoglobin in the superficial tissue.

Peggy Dotson and Matthew Livingston have Joined Kent’s Advisory Committee

Kent Imaging announced today that Peggy Dotson and Matthew Livingston have joined Kent’s advisory committee. Ms. Dotson is a business executive with over 35 years of experience in the healthcare and medical device industry. Ms. Dotson brings expertise in reimbursement analysis and strategy to the advisory committee.

Mr. Livingston has spent the last 15 years specializing in wound care and hyperbaric medicine. He has managed large in and out patient wound care centres and hyperbaric programs and is experienced in clinical research. Mr. Livingston will provide strategic guidance for the development of technologies.